| Ident. | Authors (with country if any) | Title |
|---|
| 000001 (2021) |
Daniel G. Dauner ; Kim Nichols Dauner | Summary of adverse drug events for hydroxychloroquine, azithromycin, and chloroquine during the COVID-19 pandemic. |
| 000009 (2021) |
Rashed Noor [Bangladesh] | Antiviral drugs against severe acute respiratory syndrome coronavirus 2 infection triggering the coronavirus disease-19 pandemic. |
| 000020 (2021) |
Fabio Cruciani [Italie] ; Laura Amato [Italie] ; Franco De Crescenzo ; Zuzana Mitrova [Italie] ; Rosella Saulle [Italie] ; Simona Vecchi [Italie] ; Marina Davoli [Italie] | [The praise of uncertainty: a systematic living review to evaluate the efficacy and safety of drug treatments for patients with covid-19.] |
| 000037 (2021) |
Isabel Fambuena-Muedra [Espagne] ; Marta Jiménez-García [Belgique] ; Sarah Hershko [Belgique] ; Irene Altemir-G Mez [Espagne] ; Ana Tobarra-L Pez [Espagne] | What can visual caregivers expect with patients treated for SARS-CoV-2? An analysis of ongoing clinical trials and ocular side effects. |
| 000050 (2021) |
Isabel S. Hernandes [Brésil] ; Haroldo C. Da Silva [Brésil] ; Hélio F. Dos Santos [Brésil] ; Wagner B. De Almeida [Brésil] | Unveiling the Molecular Structure of Antimalarial Drugs Chloroquine and Hydroxychloroquine in Solution through Analysis of 1H NMR Chemical Shifts. |
| 000061 (2021) |
Neils Ben Quashie [Ghana] ; Nancy Odurowah Duah-Quashie [Ghana] | Treatment of COVID-19 with Chloroquine: Implication for Malaria Chemotherapy Using ACTs in Disease Endemic Countries. |
| 000065 (2021) |
Guobing Li [République populaire de Chine, États-Unis] ; Shasha Ruan [République populaire de Chine] ; Xiaolu Zhao [République populaire de Chine] ; Qi Liu [États-Unis] ; Yali Dou [États-Unis] ; Fengbiao Mao [République populaire de Chine] | Transcriptomic signatures and repurposing drugs for COVID-19 patients: findings of bioinformatics analyses. |
| 000075 (2021) |
Sawsan Elgohary [Égypte] ; Aya A. Elkhodiry [Égypte] ; Nada S. Amin [Égypte] ; Ulrike Stein [Allemagne] ; Hend M. El Tayebi [Égypte] | Thymoquinone: A Tie-Breaker in SARS-CoV2-Infected Cancer Patients? |
| 000084 (2021) |
Bhanu Prasad Venkatesulu [États-Unis] ; Viveksandeep Thoguluva Chandrasekar [États-Unis] ; Prashanth Giridhar [Inde] ; Pragathee V [Inde] ; Harsh K. Patel [États-Unis] ; Jacob Manteuffel [États-Unis] | The mechanistic rationale of drugs, primary endpoints, geographical distribution of clinical trials against severe acute respiratory syndrome-related coronavirus-2: A systematic review. |
| 000099 (2021) |
Zelyn Lee [Canada] ; Craig R. Rayner [États-Unis, Australie] ; Jamie I. Forrest [Canada] ; Jean B. Nachega [Afrique du Sud, États-Unis, Canada] ; Esha Senchaudhuri [Canada] ; Edward J. Mills [Canada] | The Rise and Fall of Hydroxychloroquine for the Treatment and Prevention of COVID-19. |
| 000105 (2021) |
Nour K. Younis [Liban] ; Rana O. Zareef [Liban] ; Mohammad Ali N. Maktabi [Liban] ; Rami Mahfouz [Liban] | The Era of the Coronavirus Disease 2019 Pandemic: A Review on Dynamics, Clinical Symptoms and Complications, Diagnosis, and Treatment. |
| 000108 (2021) |
Masashi Ohe [Japon] ; Ken Furuya [Japon] ; Houman Goudarzi [Japon] | Tetracycline plus macrolide: A potential therapeutic regimen for COVID-19? |
| 000111 (2021) |
L. Ratiani ; S. Gegechkory ; K. Machavariani ; T. Shotadze ; T. Sanikidze [Géorgie (pays)] ; N. Intskirveli | THE PECULIARITY OF COVID- 19 GENOME AND THE CORONAVIRUS RNA TRANSLATION PROCESS AS APOTENTIAL TARGET FOR ETIOTROPIC MEDICATIONSWITH ADENINE AND OTHER NUCLEOTIDE ANALOGUES (REVIEW). |
| 000117 (2021) |
Tesia Bobrowski [États-Unis] ; Lu Chen [États-Unis] ; Richard T. Eastman [États-Unis] ; Zina Itkin [États-Unis] ; Paul Shinn [États-Unis] ; Catherine Z. Chen [États-Unis] ; Hui Guo [États-Unis] ; Wei Zheng [États-Unis] ; Sam Michael [États-Unis] ; Anton Simeonov [États-Unis] ; Matthew D. Hall [États-Unis] ; Alexey V. Zakharov [États-Unis] ; Eugene N. Muratov [États-Unis] | Synergistic and Antagonistic Drug Combinations against SARS-CoV-2. |
| 000127 (2021) |
Thirumal Kumar D [Inde] ; Nishaat Shaikh [Inde] ; Udhaya Kumar S [Inde] ; George Priya Doss C [Inde] ; Hatem Zayed [Qatar] | Structure-Based Virtual Screening to Identify Novel Potential Compound as an Alternative to Remdesivir to Overcome the RdRp Protein Mutations in SARS-CoV-2. |
| 000129 (2021) |
Sinosh Skariyachan [Inde] ; Dharshini Gopal [Inde] ; Aditi G. Muddebihalkar [Inde] ; Akshay Uttarkar [Inde] ; Vidya Niranjan [Inde] | Structural insights on the interaction potential of natural leads against major protein targets of SARS-CoV-2: Molecular modelling, docking and dynamic simulation studies. |
| 000130 (2021) |
Yudibeth Sixto-L Pez [Mexique] ; José Correa-Basurto [Mexique] ; Martiniano Bello [Mexique] ; Bruno Landeros-Rivera [France] ; Jose Antonio Garz N-Tiznado [Mexique] ; Sarita Monta O [Mexique] | Structural insights into SARS-CoV-2 spike protein and its natural mutants found in Mexican population. |
| 000135 (2021) |
Baptiste Maille [France] ; Marie Wilkin [France] ; Matthieu Million [France] ; Noémie Rességuier [France] ; Frédéric Franceschi [France] ; Linda Koutbi-Franceschi [France] ; Jérôme Hourdain [France] ; Elisa Martinez [France] ; Maxime Zabern [France] ; Christophe Gardella [France] ; Hervé Tissot-Dupont [France] ; Jagmeet P. Singh [États-Unis] ; Jean-Claude Deharo [France] ; Laurent Fiorina [France] | Smartwatch Electrocardiogram and Artificial Intelligence for Assessing Cardiac-Rhythm Safety of Drug Therapy in the COVID-19 Pandemic. The QT-logs study. |
| 000139 (2021) |
William R. Wolowich [États-Unis] ; Young M. Kwon [États-Unis] | Simulation of Drug in the Lung Can Be Misleading. |
| 000163 (2021) |
Tanvir Rahman [États-Unis] ; Quazim A. Alayo [États-Unis] ; Sibgha G. Chaudhary [États-Unis] ; Reihaneh C. Moghadam [États-Unis] ; Matthew L. German [États-Unis] ; Neil A. Ettinger [États-Unis] ; Jeremy E. Leidenfrost [États-Unis] ; Hope A. Cranston-D'Amato [États-Unis] ; Morton R. Rinder [États-Unis] ; Julianne E. Donnelly [États-Unis] | STEMI associated with SARS-CoV-2 infection and the use of ECMO as a potential therapeutic approach in addition to the PCI. |
| 000166 (2021) |
Giulia Fiscon [Italie] ; Federica Conte [Italie] ; Lorenzo Farina [Italie] ; Paola Paci [Italie] | SAveRUNNER: A network-based algorithm for drug repurposing and its application to COVID-19. |
